Science and potential alone does nothing if it’s not accompanied by relentless and smart execution. There are multiple therapies that get published in top tier journal but quite a few of them fail in the end due to bad execution and missteps from management.
This crew has lied again and again to shareholders. That alone should give anyone a pause. Once a liar always a liar.
4 plus years from data lock and no application to any other jurisdictions outside the UK is another joke. They didn’t even submit reimbursement evidence in the UK. Even a company of half a dozen people with much less funding than NWBO has had in the last 4 years would have done 2 to 3 X better.
It’s of course up to you when you want to exit, but if you plan to stick around post UK approval, at least look for signs around financial support from big pharma. If there is no upfront cash and financial backing from big pharma, I’d get out right away and not look back regardless of what BS anyone tries to sell. It would be a death spiral and shorts will certainly slam this to ground again. Try to preserve whatever capital you have left and don’t live in denial at that point!
Market Data 
Markets 
AI
